Tag: Phase II Trial
Peptide Shows Promise as an Allergen-Agnostic Treatment for Food Allergy
Revolog presents new data demonstrating long-lasting effect of '1104 candidate.
Novel Peanut Allergy Treatment Shown to be Safe, Effective, and Lasting
A unique peanut allergy immunotherapy continues to show promise for children.
Study of Boiled Peanuts Show Promise for Treatment of Peanut Allergy
OIT with boiled followed by roasted peanuts appears effective with a favorable safety profile.
Company Completes Enrollment for Phase 2 Trial of “Immune Resetting” Peptide...
Topline data anticipated in Q2 2023.
Aquestive Receives Positive FDA Response to Epinephrine Sublingual Film Phase 2...
Response confirms approach and supports the characterization of their novel drug platform.
Aquestive’s Sublingual Emergency Epinephrine Compares Favorably to EpiPen® in EPIPHAST II...
The company announced topline results from their EPIPHAST II study.
Siolta Begins Phase 2 Study in Newborns of Bacteria Consortia ...
STMC-103H has a combination of bacteria that are depleted in the gut microbiota of infants who go on to develop allergic sensitization and allergic diseases in childhood.
Aquestive Reports Positive Results from Sublingual Epinephrine Clinical Trial
Phase 2 study continues to show AQST-109 is safe and well tolerated.
Positive Early Results with Fecal Microbiota Therapy for Peanut-Allergic Patients
Encapsulated stool from non-allergic donors alters the immune system and increases tolerance to peanuts.
Revolo Biotherapeutics Announces Open Enrollment for Phase 2 Clinical Trial of...
Revolo Biotherapeutics announced it has activated clinical sites and opened enrollment in a Phase 2 clinical trial of its eosinophilic esophagitis therapy.
